At a glance
A short peptide explored in cell-aging and connective-tissue models.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source discusses cell markers related to senescence and matrix turnover. Changes in cultured cells do not demonstrate cartilage restoration or an established clinical benefit.[2][3][6]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Cartalax.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 20 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~6.67 mg/mL)
| Week/Phase | Daily Dose (mcg / mg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 2,000 mcg (2.0 mg) | 30 units (0.30 mL) |
| Weeks 3–4 | 3,000 mcg (3.0 mg) | 45 units (0.45 mL) |
| Weeks 5–8 | 4,000 mcg (4.0 mg) | 60 units (0.60 mL) |
| Weeks 9–12 | 5,000 mcg (5.0 mg) | 75 units (0.75 mL) |
Route & Frequency: Subcutaneous, once daily. Evidence note: Specific human RCT posology for SC Cartalax is limited; this schedule references preclinical fibroblast/chondrocyte studies and general SC technique guidance[2][7]. This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection volumes within typical SC tolerability parameters (≤~1.0 mL per site)[8][9].
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support connective‑tissue homeostasis and fibroblast function based on preclinical bioregulator research[2][3].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 2,000–5,000 mcg daily with gradual titration.
- Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized: refrigerate or freeze; reconstituted: refrigerate; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 2,000 mcg daily; increase by ~1,000 mcg every 2 weeks as tolerated.
- Target: 4,000–5,000 mcg daily by Weeks 5–12.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Any consistent time; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Insert needle through the stopper; let the diluent run slowly down the vial wall to avoid foaming.
- Gently swirl or roll until fully dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at 2–8 °C (35.6–46.4 °F) or freeze at −20 °C (−4 °F) for long‑term stability; protect from light and moisture[10].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Materials & quantity planning
Source materials checklist · 20 mg
Plan based on an 8–16 week daily protocol with gradual titration (average ~3.5 mg/day).
- Peptide Vials (Cartalax, 20 mg each):
- 8 weeks ≈ 10 vials
- 12 weeks ≈ 15 vials
- 16 weeks ≈ 20 vials
- Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
- Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (10 vials): 30 mL → 3 × 10 mL bottles
- 12 weeks (15 vials): 45 mL → 5 × 10 mL bottles
- 16 weeks (20 vials): 60 mL → 6 × 10 mL bottles
- Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 20 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 07
Public health resource
CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration). (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Research publication
Advances in Therapy (PubMed) — Subcutaneous injection factors and tolerability; practical volume considerations. (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Public health resource
StatPearls (NCBI Bookshelf) — Medication routes of administration; cautions for large single‑site SC volumes. (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 11
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration). (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 12
Public health resource
PubChem — Compound summary for Cartalax (AED peptide; CID 87815447): molecular formula C₁₂H₁₉N₃O₈, MW 333.29. (opens in a new tab)pubchem.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.